XORTX Files 2025 Annual Financials as Auditors Flag Going‑Concern Risk
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an announcement.
On February 26, 2026, XORTX Therapeutics Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission for February 2026, providing its consolidated financial statements for the years ended December 31, 2025, 2024 and 2023, along with management’s discussion and analysis for 2025. The filings include an unqualified audit opinion on the 2025 and 2024 financial statements but highlight a material uncertainty about the company’s ability to continue as a going concern due to its need for additional financing to fund research and development, underscoring ongoing funding risk for operations and shareholders.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.66 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Neutral.
The score is primarily constrained by weak financial fundamentals (no revenue, ongoing losses and cash burn, shrinking equity base) alongside a broadly weak technical trend (below key moving averages with negative MACD). Recent corporate actions are modest positives (capital raise and pipeline acquisition) but do not fully offset the reliance on external financing and dilution risk.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a Calgary-based biopharmaceutical company focused on researching and developing therapies, reported under International Financial Reporting Standards. As a foreign private issuer, it lists its securities with the U.S. Securities and Exchange Commission and files annual reports on Form 20-F, reflecting its cross-border capital markets focus.
Average Trading Volume: 8,477
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$3.41M
See more data about XRTX stock on TipRanks’ Stock Analysis page.
